Neurodegeneration Markers in the Cerebrospinal Fluid of 100 Patients with Schizophrenia Spectrum Disorder.
Kimon RungeAgnes BallaBernd L FiebichSimon J MaierKatharina von ZedtwitzKathrin NickelRick DerschKatharina DomschkeLudger Tebartz van ElstDominique EndresPublished in: Schizophrenia bulletin (2022)
The findings argue against a general tauopathy or amyloid pathology in patients with SSD. However, high levels of NFM, which has been linked to regulatory functions in dopaminergic neurotransmission, were associated with SSD. Therefore, NFM could be a promising candidate for further research on SSD.